Skip to main content

Grant Received for New Class of Breast Cancer Treatment

Eliot Rosen

Dr. Eliot Rosen

June 13, 2011 – The Susan G. Komen for the Cure foundation has awarded Dr. Eliot Rosen of Lombardi Comprehensive Cancer Center a $600,000 grant to research a new class of treatment for a common type of breast cancer.

Most breast cancers are fueled by estrogen and are known as estrogen-receptor-positive (ER+) cancers. Anti-estrogen drugs such as tamoxifen or those that prevent the production of estrogen in the body – such as the aromatase inhibitor anastrozole – can keep cancer at bay.

But Rosen’s team of researchers has found that the tumor suppressor protein from a gene called BRCA1 binds tightly to the estrogen receptor protein – inhibiting its activity and stopping the growth of ER-positive breast cancer cells.

“We are hopeful that our compounds can be developed into drugs that will be useful both for breast cancer prevention and for treatment, particularly for anti-estrogen-resistant cancers, either by themselves or in combination with conventional anti-estrogen agents,” says Rosen, who holds the Gragnani Chair in Oncology and Radiation Biology.

The Komen for the Cure grant funds the critical next steps in Rosen’s research.

Georgetown University37th and O Streets, N.W., Washington D.C. 20057(202) 687.0100

Connect with us via: